TY - JOUR
T1 - In vitro hemocompatibility testing of dyneema purity fibers in blood contact
AU - Basir, Amir
AU - de Groot, Philip G.
AU - Grundeman, Paul F.
AU - Tersteeg, Claudia
AU - Maas, Coen
AU - Barendrecht, Arjan
AU - Van Herwaarden, Joost
AU - Kluin, Jolanda
AU - Moll, Frans
AU - Pasterkamp, Gerard
AU - Roest, Mark
PY - 2015/5/1
Y1 - 2015/5/1
N2 - Objective: Heart valve and vascular prosthesis implantation is a common procedure for patients with heart valve stenosis or regurgitation and dilated or obstructive vascular disease. Drawbacks of conventional valve prostheses are the requirement for anticoagulant drugs, moderate durability, and suboptimal resistance to fatigue and tear. Dyneema Purity fibers are made from ultra-high-molecularweight polyethylene filaments and are very thin, flexible, and fatigue and abrasion resistant and have high strength. Therefore, prostheses made from Dyneema Purity fibers might be attractive for use in the minimally invasive treatment of valvular- and vascular diseases. The aim of this study was to test the hemocompatibility of Dyneema Purity fibers in contact with blood. Methods: Real-time platelet adhesion in human blood of 3 volunteers was quantified after 5 minutes of perfusion on single filaments (Ø 15 μm) of Dyneema Purity and polyester fibers. Plasma thrombin generation was measured by fluoroscopy for patches of Dyneema Purity fibers and for 5 commonly used polyester and expanded polytetrafluoroethylene cardiovascular prostheses. Results: Platelet adhesion per 1 mm was 6 ± 1.4 on Dyneema Purity filaments and 15 ± 3.4 on polyester filaments (P = 0.02). Total formed thrombin and the time to peak of its maximum were noninferior for patches of Dyneema Purity fibers compared with the reference materials. Conclusions: Dyneema Purity fibers are noninferior in adhesion and coagulation activation compared with commonly used cardiovascular prostheses.
AB - Objective: Heart valve and vascular prosthesis implantation is a common procedure for patients with heart valve stenosis or regurgitation and dilated or obstructive vascular disease. Drawbacks of conventional valve prostheses are the requirement for anticoagulant drugs, moderate durability, and suboptimal resistance to fatigue and tear. Dyneema Purity fibers are made from ultra-high-molecularweight polyethylene filaments and are very thin, flexible, and fatigue and abrasion resistant and have high strength. Therefore, prostheses made from Dyneema Purity fibers might be attractive for use in the minimally invasive treatment of valvular- and vascular diseases. The aim of this study was to test the hemocompatibility of Dyneema Purity fibers in contact with blood. Methods: Real-time platelet adhesion in human blood of 3 volunteers was quantified after 5 minutes of perfusion on single filaments (Ø 15 μm) of Dyneema Purity and polyester fibers. Plasma thrombin generation was measured by fluoroscopy for patches of Dyneema Purity fibers and for 5 commonly used polyester and expanded polytetrafluoroethylene cardiovascular prostheses. Results: Platelet adhesion per 1 mm was 6 ± 1.4 on Dyneema Purity filaments and 15 ± 3.4 on polyester filaments (P = 0.02). Total formed thrombin and the time to peak of its maximum were noninferior for patches of Dyneema Purity fibers compared with the reference materials. Conclusions: Dyneema Purity fibers are noninferior in adhesion and coagulation activation compared with commonly used cardiovascular prostheses.
KW - Coagulation activation
KW - Hemocompatibility testing
KW - Platelet adhesion
KW - Prosthetic heart valve replacement
KW - Ultra-high-molecular-weight polyethylene
UR - http://www.scopus.com/inward/record.url?scp=84942898638&partnerID=8YFLogxK
U2 - 10.1097/IMI.0000000000000163
DO - 10.1097/IMI.0000000000000163
M3 - Meeting Abstract
C2 - 26181583
AN - SCOPUS:84942898638
SN - 1556-9845
VL - 10
SP - 195
EP - 201
JO - Innovations (Philadelphia, Pa.)
JF - Innovations (Philadelphia, Pa.)
IS - 3
ER -